EHA21: Study raises BMS’ hopes for Reblozyl in less severe diseaseBristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after Share XEHA21: Study raises BMS’ hopes for Reblozyl in less severe diseasehttps://pharmaphorum.com/news/eha21-study-raises-bms-hopes-for-reblozyl-in-less-severe-patients/
CHMP backs BMS’ first-in-class anaemia drug ReblozylBristol-Myers Squibb has moved a step closer to EMA approval of Reblozyl, a therapy for anaemia that has Share XCHMP backs BMS’ first-in-class anaemia drug Reblozylhttps://pharmaphorum.com/news/chmp-backs-bms-first-in-class-anaemia-drug-reblozyl/
Celgene gets speedy review for thalassaemia drug luspaterceptIt’s shaping up to be a landmark year for the community of patients with rare blood disorder beta Share XCelgene gets speedy review for thalassaemia drug luspatercepthttps://pharmaphorum.com/news/celgene-gets-speedy-review-for-thalassaemia-drug-luspatercept/
Celgene files potential blockbuster luspaterceptCelgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up Share XCelgene files potential blockbuster luspatercepthttps://pharmaphorum.com/news/celgene-files-potential-blockbuster-luspatercept/
Celgene scores at ASH18 with double luspatercept dataA pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have Share XCelgene scores at ASH18 with double luspatercept datahttps://pharmaphorum.com/news/celgene-scores-at-ash18-with-double-luspatercept-data/
